SCHEMBL4821885

SCHEMBL4821885

CC(C)CCCC(C)CCCCCO

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
BLM P54132 1/20 0.50
PTPN1 P18031 3/20 0.48
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 1/20 0.38
ACE2 Q9BYF1 1/20 0.38
PRKD3 O94806 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCH P24723 1/20 0.33
PRKCI P41743 1/20 0.33
PRKCE Q02156 1/20 0.33
PRKCQ Q04759 1/20 0.33
PRKCZ Q05513 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12960699 1.00 LMNA (0.70) LMNABLMPTPN1MEN1KMT2A
Squalane SCHEMBL28103427 1.00 LMNA (0.70) LMNABLMPTPN1MEN1KMT2A
SCHEMBL16167217 1.00 LMNA (0.70) LMNABLMPTPN1MEN1KMT2A
SCHEMBL9060842 1.00 LMNA (0.70) LMNABLMPTPN1MEN1KMT2A
SCHEMBL3568842 0.97 LMNA (0.74) LMNABLMPTPN1MEN1KMT2A
SCHEMBL28228861 0.97 LMNA (0.74) LMNABLMPTPN1MEN1KMT2A
SCHEMBL3575766 0.97 LMNA (0.74) LMNABLMPTPN1MEN1KMT2A
SCHEMBL1301687 0.93 LMNA (0.59) LMNABLMPTPN1MEN1KMT2A
Squalane SCHEMBL8558537 0.91 LMNA (0.58) LMNABLMPTPN1MEN1KMT2A
SCHEMBL10535028 0.90 LMNA (0.68) LMNABLMPTPN1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996904-A Process for preparing conjugated dienes from allyl alcohol 奇华顿股份有限公司 2023-04-21 CN disclosed
US-7345205-B2 Method for the production of tetrahydrogeranylacetone BASF AKTIENGESELLSCHAFT (DE) 2008-03-18 US disclosed
EP-1523467-B1 METHOD FOR THE PRODUCTION OF TETRAHYDROGERANYLACETONE BASF AG (DE) 2007-11-14 EP disclosed
US-20060211898-A1 Method for the production of tetrahydrogeranylacetone BASF AKTIENGESELLSCHAFT (DE) 2006-09-21 US disclosed
EP-1523467-A1 METHOD FOR THE PRODUCTION OF TETRAHYDROGERANYLACETONE BASF AKTIENGESELLSCHAFT (DE) 2005-04-20 EP disclosed
WO-2004007413-A1 METHOD FOR THE PRODUCTION OF TETRAHYDROGERANYLACETONE BASF AKTIENGESELLSCHAFT (DE) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211898-A1 Method for the production of tetrahydrogeranylacetone GNPAT, GGPS1, FNTA LMNA 2627/4885BLM 3558/4885PTPN1 4867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.